Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Toxicity Clear all
Recruiting Not applicable Interventional

Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences

NCT04650256
View directory record Official record
Conditions
Skin Toxicity
Interventions
Complementary and alternative medicine (CAM)
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 25, 2026, 1:56 PM EDT
Completed No phase listed Observational

Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS

NCT00106795
View directory record Official record
Conditions
HIV Infections, Fatigue, HIV Positive, AIDS, Healthy Volunteer, HV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Not applicable Interventional

EHR-embedded OCDT in Breast or GI Cancer

NCT03858712
View directory record Official record
Conditions
Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions
Active Care Team Alert, Passive Care Team Alert
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Jun 25, 2026, 1:56 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

NCT01160445
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Renal Cancer
Interventions
Zanolimumab, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jun 25, 2026, 1:56 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene - Usual, Raloxifene - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 25, 2026, 1:56 PM EDT
Active, not recruiting No phase listed Observational Results available

Assessing the Time Demands of Cancer

NCT05708703
View directory record Official record
Conditions
Metastatic Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

NCT00003068
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride, thiotepa, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 2 Interventional

Vinorelbine in Treating Older Women With Stage IV Breast Cancer

NCT00022152
View directory record Official record
Conditions
Breast Cancer
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

NCT00109005
View directory record Official record
Conditions
Melanoma
Interventions
Revlimid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Jun 25, 2026, 1:56 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

NCT02795143
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Isotretinoin, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

NCT02831582
View directory record Official record
Conditions
Arthralgia, Breast Neoplasms
Interventions
Omega-3 Fatty Acid, Placebo
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Duarte, California • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Jun 25, 2026, 1:56 PM EDT
Recruiting Phase 4 Interventional

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

NCT07158164
View directory record Official record
Conditions
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Gastro-Intestinal Intraepithelial Neoplasia
Interventions
Fluorouracil injection, Xeloda
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jun 25, 2026, 1:56 PM EDT
Recruiting Phase 2 Interventional

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164
View directory record Official record
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jun 25, 2026, 1:56 PM EDT
Completed No phase listed Observational

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

NCT01407770
View directory record Official record
Conditions
Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities
Interventions
DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay, flow cytometry, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, assessment of therapy complications, quality-of-life assessment, 3-dimensional conformal radiation therapy, breast irradiation, external beam radiation therapy, hypofractionated radiation therapy, intensity-modulated radiation therapy, whole breast irradiation
Genetic · Other · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jun 25, 2026, 1:56 PM EDT
Completed No phase listed Observational

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

NCT01416688
View directory record Official record
Conditions
Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions
assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
113
States / cities
Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jun 25, 2026, 1:56 PM EDT
Not yet recruiting Not applicable Interventional

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

NCT07553234
View directory record Official record
Conditions
Breast Cancer
Interventions
Stool Sampling, Chia Seeds
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Not applicable Interventional

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

NCT05403736
View directory record Official record
Conditions
Cancer
Interventions
Cardiac Aggressive Risk MitigAtion Plan
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 25, 2026, 1:56 PM EDT
Terminated Phase 2 Interventional Results available

Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer

NCT00090844
View directory record Official record
Conditions
Breast Cancer, Hormone Changes, Drug Toxicity
Interventions
triptorelin
Drug
Lead sponsor
University of South Florida
Other
Eligibility
Up to 44 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Oakland, California • Tampa, Florida • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jun 25, 2026, 1:56 PM EDT
Terminated Phase 4 Interventional

Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

NCT00699101
View directory record Official record
Conditions
Breast Cancer
Interventions
Conture Multi-Lumen Balloon
Device
Lead sponsor
SenoRx, Inc.
Industry
Eligibility
50 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Jun 25, 2026, 1:56 PM EDT
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 25, 2026, 1:56 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 25, 2026, 1:56 PM EDT
Recruiting Not applicable Interventional

Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

NCT05984888
View directory record Official record
Conditions
Breast Cancer
Interventions
MIND Diet Intervention Group, General Health Curriculum (GHC) Group
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Jun 25, 2026, 1:56 PM EDT